Skip to content

NovoCure NVCR Debt-to-assets

Debt-to-assets at other companies

Boston Scientific logo
Boston ScientificBSX
-0.3×
Medtronic logo
MedtronicMDT
0.3×0.0×
Iovance Biotherapeutics, Inc. logo
Iovance Biotherapeutics, Inc.IOVA
0.1×0.0×
Nuvation Bio logo
Nuvation BioNUVB
0.1×+0.1×
Vir Biotechnology, Inc. logo
Vir Biotechnology, Inc.VIR
0.1×0.0×
Syndax Pharmaceuticals logo
Syndax PharmaceuticalsSNDX
0.7×+0.2×

Other financials

Income statement

See full
Revenue$174.1M+12.3%
Gross profit$135.1M+16.0%
Operating income-$67.4M-78.1%
Net income-$71.1M-107%
EPS (diluted)-$0.62-100%

Balance sheet

See full
Cash & equivalents$87.5M-31.2%
Total debt$39.5M-2.1%
Total equity$330.7M-8.6%
Total assets$787.9M-36.9%

Cash flow

See full
Operating cash flow-$13.5M+62.1%
CapEx$5.2M-51.4%
Free cash flow-$18.7M+59.7%

Valuation

See full
Market cap$1.7B-36.7%

Profitability

See full
Gross margin75.2%-2.0pp
Operating margin-27.2%+0.4pp
Net margin-25.7%-0.7pp
FCF margin-7.1%-2.0pp

Returns & leverage

See full
Return on equity-50%+5.4pp
Debt / equity0.1×0.0×
Current ratio2.9×+1.4×

Where this comes from

Calculated from NovoCure’s reported figures.

Based on the most recent quarter.

The official record: NovoCure’s 10-Q, filed April 30, 2026, on SEC EDGAR. View the filing →

Ask your AI about NovoCure's debt-to-assets.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is NovoCure's debt-to-assets?
NovoCure (NVCR) reported debt-to-assets of 0.1× in Q1 2026.
How has NovoCure's debt-to-assets changed year-over-year?
NovoCure's debt-to-assets increased by 55.1% year-over-year, from 0× to 0.1×.
What is the long-term trend for NovoCure's debt-to-assets?
Over 5 years (2020 to 2025), NovoCure's debt-to-assets has grown at a -31.1% compound annual growth rate (CAGR), from 0.4× to 0.1×.
What does debt-to-assets mean?
Total debt divided by total assets at the quarter end. Measures the share of the asset base financed by debt.